氨甲环酸未增加高危髋部骨折关节置换患者并发症风险
本研究回顾性分析了2011至2019年间在四家医院因移位型股骨颈骨折行髋关节置换术的患者,按风险分层和是否使用氨甲环酸分组,采用倾向性评分调整后比较高危组(n=1,066)及全人群(n=2,166)术后90天内血栓并发症和死亡率。结果显示,氨甲环酸使用与高危组及全人群血栓并发症或死亡率增加均无关联。
要点
- 高危髋部骨折关节置换患者使用氨甲环酸不增加90天内死亡率或血栓事件风险。
- 倾向性匹配的高危组中,使用与未使用氨甲环酸者死亡率分别为10.00%与14.82%(p=0.295)。
- 深静脉血栓、肺栓塞、心肌梗死和卒中发生率在两组间均无显著差异。
核心结论
- 在高危髋部骨折关节置换患者中,氨甲环酸使用与术后90天内死亡率、深静脉血栓、肺栓塞、心肌梗死或卒中风险增加无关。
研究设计与样本
- 回顾性队列研究,纳入2011至2019年间4个院区因移位型股骨颈骨折行半髋或全髋置换的患者,按风险(高危/低危)和氨甲环酸使用分组,采用倾向性评分进行风险调整,比较高危组(n=1,066)和全人群(n=2,166)。
主要发现
- 在1,066例倾向性匹配的高危患者中,未使用与使用氨甲环酸者死亡率分别为14.82%和10.00%(p=0.295),深静脉血栓3.56%和3.04%(p=0.440),肺栓塞2.44%和1.96%(p=0.374),心肌梗死3.38%和2.14%(p=0.704),卒中4.32%和5.71%(p=0.225)。
- 在全人群及高危组中,氨甲环酸使用均未与术后90天内血栓并发症或死亡率增加相关。
关键数值与推荐
- 高危组倾向性匹配样本量n=1,066,全人群n=2,166。
- 结局指标为术后90天内死亡率、深静脉血栓、肺栓塞、心肌梗死和卒中。
临床怎么用
- 对于因移位型股骨颈骨折需行关节置换的高危患者,可考虑使用氨甲环酸而不必担心增加血栓并发症或死亡风险。
局限性
- 本研究为回顾性设计,证据等级为治疗性III级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tranexamic acid (TXA) is considered safe and efficacious for elective total joint arthroplasty. However, evidence of TXA's safety in high-risk patients with hip fracture requiring nonelective arthroplasty has been lacking. This study aimed to assess whether TXA administration to high-risk patients with a hip fracture requiring arthroplasty increased the risk of thrombotic complications or mortality. METHODS: All patients who underwent hip hemiarthroplasty (HHA) or total hip arthroplasty (THA) for displaced femoral neck fractures between 2011 and 2019 at 4 sites within 1 hospital system were retrospectively identified. Patients were grouped by risk (high-risk or low-risk) and TXA treatment (with or without TXA). Propensity scores were used for risk adjustment in comparisons between surgery with and without TXA for only the high-risk group (n = 1,066) and the entire population (n = 2,166). Differences in the occurrence of postoperative mortality, deep venous thrombosis, pulmonary embolism, myocardial infarction, and stroke within 90 days of hip arthroplasty were evaluated. RESULTS: TXA administration was not associated with an increased risk of thrombotic complications or mortality within 90 days in either high-risk or all-patient groups. Specifically, among 1,066 matched high-risk patients who did not or did receive TXA, there were no significant differences in mortality (14.82% and 10.00%; p = 0.295), deep venous thrombosis (3.56% and 3.04%; p = 0.440), pulmonary embolism (2.44% and 1.96%; p = 0.374), myocardial infarction (3.38% and 2.14%; p = 0.704), or stroke (4.32% and 5.71%; p = 0.225). CONCLUSIONS: In our review of 1,066 propensity-matched high-risk patients undergoing hip arthroplasty for displaced femoral neck fractures, we found that TXA administration (compared with no TXA administration) was not associated with an increased risk of mortality, deep venous thrombosis, pulmonary embolism, myocardial infarction, or stroke. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
引用
- Porter SB, Spaulding AC, Duncan CM, et al. Tranexamic Acid Was Not Associated with Increased Complications in High-Risk Patients with Hip Fracture Undergoing Arthroplasty. J Bone Joint Surg Am. 2021. PMID: 34449443. doi:10.2106/JBJS.21.00172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。